Home
/

Sarcopenia

REVIEWED BY
Bill Maish, MD
Clinical Content Consultant
Published
May 31, 2026
Last updated
May 30, 2026
Key takeaway:

Blood testing for sarcopenia measures IGF-1, Testosterone, and Albumin to assess the anabolic signaling, androgen status, and protein reserve that drive skeletal muscle maintenance. Low-normal values tilt physiology catabolic and are associated with declining strength, slower recovery, fatigue, and reduced bone density. Tracking these markers alongside strength and body composition data helps quantify sarcopenia risk and anticipate disability with aging.

Read more →
Table of contents

Sarcopenia and the Anabolic Signals That Defend Muscle

Sarcopenia biomarkers are blood signals that map the biology of age‑related muscle loss. They show how much muscle you have, how actively it’s being renewed, and whether your body is leaning toward building or breaking down. Some come directly from muscle and reflect quantity (creatinine) and local growth brakes or accelerators (myostatin, follistatin). Others capture whole‑body forces that shape muscle health—anabolic drivers that support repair and synthesis (IGF‑1, testosterone) and inflammatory cues that push tissue toward breakdown (C‑reactive protein, interleukin‑6, TNF‑α). Nutrient‑hormone supports reveal readiness of the muscle system (vitamin D). Pairing signals can sharpen the picture—comparing a muscle‑linked marker with one not tied to muscle (creatinine with cystatin C) helps estimate true muscle mass behind routine numbers. Together, these biomarkers translate invisible shifts in skeletal muscle biology into measurable data, enabling earlier recognition of sarcopenia, more tailored exercise and nutrition strategies, and objective tracking of change over time.

Why IGF-1, Testosterone, and Albumin Carry Weight for Muscle

Sarcopenia blood biomarkers capture how your body builds, repairs, and preserves muscle across systems. Insulin-like growth factor 1 (IGF-1) signals anabolic drive, testosterone supports muscle fiber size and strength, and albumin reflects protein reserve and inflammation. Together they mirror the muscle–endocrine–immune network that influences mobility, glucose handling, bone health, and resilience with aging.Within age- and sex-specific reference ranges, IGF-1 that sits in the mid-to-upper range often aligns with better muscle protein synthesis. Testosterone in the sex-appropriate mid-range supports strength and recovery in men; women benefit from adequate physiologic androgen levels without exceeding normal. Albumin is most informative when solidly within the normal range; low-normal can hint at systemic inflammation or inadequate protein status, while “high” albumin usually reflects dehydration rather than extra muscle.When these values are low, physiology tilts catabolic. Low IGF-1 or testosterone signals reduced synthesis and accelerated loss of lean mass—felt as declining strength, slower recovery, fatigue, and, over time, poorer balance and bone density. Men may notice diminished morning erections and vigor; women may experience low energy and reduced exercise tolerance; older adults face higher fall and frailty risk. Low albumin often marks inflammation or malnutrition, with edema and slower wound healing. Unusually high IGF-1 or testosterone can indicate endocrine disorders and may bring acne, fluid retention, or metabolic strain; elevated albumin typically indicates underhydration. Teens naturally have higher IGF-1 during growth, and pregnancy lowers albumin via hemodilution, so interpretation must be contextual.Big picture: these markers connect muscle to metabolism, hormones, and immunity. Monitoring them alongside strength and gait measures helps quantify sarcopenia risk, anticipate disability, diabetes and cardiovascular complications, and understand long-term health trajectory.

The Honest Reach of Blood Tests for Sarcopenia

Sarcopenia blood testing provides insight into the body’s ability to maintain muscle mass, strength, and function—key elements for overall vitality, mobility, and resilience as we age. Muscle health is deeply connected to energy metabolism, cardiovascular stability, cognitive performance, and immune defense. At Superpower, we assess three core biomarkers for sarcopenia risk: IGF-1, Testosterone, and Albumin.IGF-1 (Insulin-like Growth Factor 1) is a hormone that signals muscle growth and repair, reflecting the body’s anabolic (building) capacity. Testosterone, present in all genders but at higher levels in males, also drives muscle protein synthesis and supports muscle maintenance. Albumin, a major blood protein, indicates overall nutritional status and the body’s ability to build and repair tissues, including muscle.Healthy levels of IGF-1 and testosterone support stable muscle mass and function, helping to prevent the gradual loss of muscle (sarcopenia) that can compromise mobility and independence. Albumin acts as a marker of systemic stability; low levels may signal chronic illness, inflammation, or malnutrition, all of which can accelerate muscle loss. Together, these biomarkers provide a window into the body’s capacity to preserve muscle and adapt to physical demands.Interpretation of these results depends on factors such as age, sex, acute or chronic illness, medication use (like steroids or hormone therapy), and laboratory assay differences. For example, normal ranges shift with age and between sexes, and temporary changes can occur during illness or recovery.

FAQs

Sarcopenia blood testing evaluates the biology behind muscle loss. Superpower measures IGF-1, Testosterone, and Albumin. IGF-1 reflects growth hormone signaling and anabolic drive. Testosterone reflects androgen status, which influences muscle protein synthesis and strength. Albumin reflects protein nutrition, liver synthetic function, and systemic inflammation. Together, these biomarkers show whether reduced muscle mass and function stem from impaired anabolic signaling, endocrine deficiency, malnutrition, inflammation, or chronic illness. Blood testing does not diagnose sarcopenia on its own; it complements clinical measures of muscle mass and performance.

It clarifies why muscle is being lost. Low IGF-1 points to weak anabolic signaling or energy deficiency, low Testosterone signals androgen insufficiency, and low Albumin suggests poor protein status, inflammation, or liver disease. Knowing the driver helps target evaluation and track risk for frailty, falls, and functional decline. Trends over time show whether biology is stabilizing or worsening and whether a plan is changing physiology. Superpower provides IGF-1, Testosterone, and Albumin to ground your sarcopenia assessment in objective biology.

Yes. With Superpower, our team member can organize a professional blood draw in your home. You get IGF-1, Testosterone, and Albumin testing without visiting a clinic, with standard handling and lab analysis for accuracy.

Start with a baseline. Recheck periodically to confirm trends, typically every 6–12 months, and sooner if there are rapid changes in strength, weight, illness, or when starting or adjusting therapies. Testosterone is diurnal and best tracked with consistent morning draws; IGF-1 changes more slowly; Albumin reflects longer-term protein status and inflammation. Frequency should match your clinical context and the pace of change you’re seeing.

Age, sex, and circadian rhythm affect hormones, with Testosterone peaking in the morning. Acute illness, chronic inflammation, liver or kidney disease, thyroid disorders, diabetes, and hydration status influence IGF-1 and Albumin. Energy and protein intake, rapid weight changes, and recent strenuous exercise can shift values. Medications such as glucocorticoids, opioids, androgens, or growth hormone therapies alter results. Posture and tourniquet time at draw can slightly change Albumin due to fluid shifts.

Aim for a morning draw between 7–10 AM for Testosterone consistency. An 8–12 hour fast helps standardize IGF-1 and Albumin; drink water normally to avoid dehydration skewing Albumin. Avoid unusually intense exercise the day before and major alcohol intake. Rest seated for several minutes before the draw. Continue prescribed medicines unless your clinician advises otherwise, but be aware that steroids, androgens, and growth hormone can affect results.

References

  1. Cruz-Jentoft, A. J., Bahat, G., Bauer, J., Boirie, Y., Bruyère, O., Cederholm, T., ... Zamboni, M. (2019). Sarcopenia: Revised European consensus on definition and diagnosis. Age and Ageing, 48(1), 16-31. https://doi.org/10.1093/ageing/afy169
  2. Shigehara, K., Kato, Y., Izumi, K., & Mizokami, A. (2022). Relationship between testosterone and sarcopenia in older-adult men: A narrative review. Journal of Clinical Medicine, 11(20), 6202. https://doi.org/10.3390/jcm11206202
  3. Jiang, J. J., Chen, S. M., Chen, J., Wu, L., Ye, J. T., & Zhang, Q. (2022). Serum IGF-1 levels are associated with sarcopenia in elderly men but not in elderly women. Aging Clinical and Experimental Research, 34(10), 2465-2471. https://doi.org/10.1007/s40520-022-02180-2
  4. Kashani, K. B., Frazee, E. N., Kukrálová, L., Sarvottam, K., Herasevich, V., Young, P. M., ... Lieske, J. C. (2017). Evaluating muscle mass by using markers of kidney function: Development of the sarcopenia index. Critical Care Medicine, 45(1), e23-e29. https://doi.org/10.1097/CCM.0000000000002013
  5. Ding, J., Yang, G., Sun, W., Li, Y., Wang, N., Wang, J., & Zhao, Y. (2024). Association of interleukin-6 with sarcopenia and its components in older adults: A systematic review and meta-analysis of cross-sectional studies. Annals of Medicine, 56(1), 2384664. https://doi.org/10.1080/07853890.2024.2384664

Built by the world’s top doctors and scientists

Dr Anant Vinjamoori, MD

Chief Longevity Officer, Superpower

Board-certified longevity physician. Previously product leader at Virta Health & CMO at Modern Age. Featured in  WSJ, Forbes, and Fortune.

Learn more

Dr Leigh Erin Connealy, MD

Clinician & Founder of The Centre for New Medicine

Leads the largest integrative medical clinic in North America. A pioneer in integrative oncology.

Learn more

Dr Robert Lufkin

UCLA Medical Professor, NYT Bestselling Author

A leading voice on metabolic health and longevity as shown in The Today Show, USA Today and FOX.

Learn more

Dr Abe Malkin

Founder & Medical Director of Concierge MD

Leads a nationwide medical practice, and Drip Hydration, a mobile IV therapeutics company

Learn more
Membership slide 1
Membership slide 1
Membership slide 2
Membership slide 3
1 / 3

Your membership starts here

Annual 100+ biomarker panel

Data dashboard and digital twin

Upload past labs and connect wearables

Personalized health protocol

24/7 care team access

AI companion for all health questions

Marketplace with additional solutions

$199

/year*

Billed annually

HSA/ FSA eligible
Cancel anytime
Results in a week

* Pricing may vary for members in New York and New Jersey